Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
2006
Tissue production of pro-inflammatory cytokines (IL-1 , TNF and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
2003
Serum nm23-H1 Protein as a Prognostic Factor in Hematological Malignancies
2002
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas
2004
Classification of Cutaneous Lymphoma
1999
Molecular mechanisms of drug resistance
2005
bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related.
1998
Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients
2016
Clinicopathologic Analysis of CD10+ and CD10– Diffuse Large B-Cell Lymphoma
2001
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
1999 Standout
Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy
2005 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Trial of Tocilizumab in Giant-Cell Arteritis
2017 Standout
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
2001 Standout
Genetic analysis of chemoresistance in primary murine lymphomas
2000
A uniform activated B-cell–like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
2005
Cellular survival: a play in three Akts
1999 Standout
Tumor Cell Metabolism: Cancer's Achilles' Heel
2008 Standout
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Medium- and Large-Vessel Vasculitis
2003
The Bcl2 family: regulators of the cellular life-or-death switch
2002 Standout
HSP90 and the chaperoning of cancer
2005 Standout
Effective Immunochemotherapy For Aggressive Non-Hodgkin’s Lymphoma
2004
Bcl-2 Family Proteins: Strategies for Overcoming Chemoresistance in Cancer
1997
Bcl-2 family proteins
1998
The biochemistry of apoptosis
2000 StandoutNature
BCL-2 family members and the mitochondria in apoptosis
1999 Standout
Primary Cutaneous Diffuse Large B-Cell Lymphoma
2002
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
2002 Standout
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
2004
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
2003
Overexpression of Bcl-xL Promotes Chemotherapy Resistance of Mammary Tumors in a Syngeneic Mouse Model
1999
CD95(APO-1/Fas)-Mediated Apoptosis: Live and Let Die
1998
Death receptors in chemotherapy and cancer
2004
Four deaths and a funeral: from caspases to alternative mechanisms
2001 Standout
Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance
2003
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
2016
World Health Organization classification of hematopoietic and lymphoid tissues: Implications for dermatology
2003
Bcl-2 antisense therapy in B-cell malignancies
2005
Apoptosis
2002 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
Death and anti-death: tumour resistance to apoptosis
2002 Standout
Oxidative Stress in Cancer
2020 Standout
Molecular signals in anti-apoptotic survival pathways
2001
CD95(APO-1/Fas)-Mediated Apoptosis in Normal and Malignant Liver, Colon, and Hematopoietic Cells
1998
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas
2002
Causes and Consequences ofBCL2Overexpression in Diffuse Large B-Cell Lymphoma
2001
Primary brain tumours in adults
2012 Standout
Dysregulation of apoptosis genes in hematopoietic malignancies
2002
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
2003 Standout
The Bcl-2 apoptotic switch in cancer development and therapy
2007 Standout
Escaping Cell Death: Survival Proteins in Cancer
1999
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
2006 Standout
Baboon T cell lymphomas expressing the B cell-associated surface proteins CD40 and Bgp95
1992
Calreticulin exposure dictates the immunogenicity of cancer cell death
2006 Standout
The TRA-1A Sex Determination Protein of C. elegans Regulates Sexually Dimorphic Cell Deaths by Repressing the egl-1 Cell Death Activator Gene
1999 StandoutNobel
Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis
2002 StandoutNobel
CD40 ligand is a T cell growth factor
1993 StandoutNobel
Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
2011
Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
2017
Prognostic Significance of Ki-67 Nuclear Proliferative Antigen, bcl-2 Protein, and p53 Expression in Follicular and Diffuse Large B-Cell Lymphoma
2001
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
1998
Primary and Secondary Cutaneous Diffuse Large B-Cell Lymphomas
2003
The Bcl-2 Protein Family: Arbiters of Cell Survival
1998 StandoutScience
2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease
2010 Standout
Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity.
2000
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
2001
Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
2000
Apoptosis: A Review of Programmed Cell Death
2007 Standout
Revised Response Criteria for Malignant Lymphoma
2007 Standout
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Apoptosis and the Dilemma of Cancer Chemotherapy
1997
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
2006
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
2002
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
2005
Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression.
1997
Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
1998
Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma
1997
Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
1998
Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma
2001
Mammalian Caspases: Structure, Activation, Substrates, and Functions During Apoptosis
1999 Standout
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma
1997
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma
2001
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma
2000
Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms
1999 StandoutScience
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
2002
Prognostic Significance of Bax Protein Expression in Diffuse Aggressive Non-Hodgkin's Lymphoma
1997
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
2007
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
2002
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Design of the Tocilizumab in Giant Cell Arteritis Trial
2013
Works of C Lavignac being referenced
Production of interleukin 6 by granulomas of giant cell arteritis
1994
Étude immunohistochimique des lésions d'artérite temporale de Horton avant et au cours de la corticothérapie *
1996
Constitutive IL-2 expression in HTLV-I-infected leukaemic T cell lines.
1991
Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)
1996
Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)
1996